EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia

Hisanori Kanazawa iD, Seiji Takashio iD, Tadashi Hoshiyama, Miwa Ito iD, Shozo Kaneko iD, Takuya Kiyama iD, Yusei Kawahara, Hitoshi Sumi iD, Yuichiro Tsuruta iD, Naoto Kuyama iD, Kyoko Hirakawa iD, Masanobu Ishii iD und 14 weitere

Europace · 03.06.2024 · 26 (6)

DOI: 10.1093/europace/euae155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Europace, online erschienen am 27.06.2024. Verfasst von Hisanori Kanazawa und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan. Hauptthemen laut MEDLINE: Catheter Ablation, Atrial Flutter, Atrial Fibrillation, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF). This study aimed to investigate the outcomes of catheter ablation (CA) for AF/AFL/AT in patients with ATTRwt-CM and propose a treatment strategy for CA. Methods and results A cohort study was conducted on 233 patients diagnosed with ATTRwt-CM, including 54 who underwent CA for AF/AFL/AT. The background of each arrhythmia and the details of the CA and its outcomes were investigated. The recurrence-free rate of AF/AFL/AT overall in ATTRwt-CM patients with multiple CA was 70.1% at 1-year, 57.6% at 2-year, and 44.0% at 5-year follow-up, but CA significantly reduced all-cause mortality [hazard ratio (HR): 0.342, 95% confidence interval (CI): 0.133–0.876, P = 0.025], cardiovascular mortality (HR: 0.378, 95% CI: 0.146–0.981, P = 0.045), and HF hospitalization (HR: 0.488, 95% CI: 0.269–0.889, P = 0.019) compared with those without CA. There was no recurrence of the cavotricuspid isthmus (CTI)–dependent AFL, non-CTI–dependent simple AFL terminated by one linear ablation, and focal AT originating from the atrioventricular (AV) annulus or crista terminalis eventually. Twelve of 13 patients with paroxysmal AF and 27 of 29 patients with persistent AF did not have recurrence as AF. However, all three patients with non-CTI–dependent complex AFL not terminated by a single linear ablation and 10 of 13 cases with focal AT or multiple focal ATs originating beyond the AV annulus or crista terminalis recurred even after multiple CA.

Conclusion

The outcomes of CA for ATTRwt-CM were acceptable, except for multiple focal AT and complex AFL. Catheter ablation may be aggressively considered as a treatment strategy with the expectation of improving mortality and hospitalization for HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Catheter AblationAtrial FlutterAtrial FibrillationAmyloid Neuropathies, FamilialCardiomyopathiesHumansMaleFemaleAgedTreatment OutcomeMiddle AgedRecurrenceTachycardia, SupraventricularRetrospective StudiesPrealbumin

Stichwörter der Autor:innen

Atrial fibrillationAtrial flutterAtrial tachycardiaCatheter ablationWild-type transthyretin amyloid cardiomyopathy

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
  • Department of Cardiac Arrhythmias, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.

ORCID-Profile: Hisanori Kanazawa, Seiji Takashio, Miwa Ito, Shozo Kaneko, Takuya Kiyama, Hitoshi Sumi, Yuichiro Tsuruta, Naoto Kuyama, Kyoko Hirakawa, Masanobu Ishii, Kenshi Yamanaga, Koichiro Fujisue, Shinsuke Hanatani, Daisuke Sueta, Yuichiro Arima, Satoshi Araki, Hiroki Usuku, Taishi Nakamura, Kenichi Matsushita, Kenichi Tsujita

Förderung

  • JSPS KAKENHI

Zitieren

APA

Kanazawa, H., Takashio, S., Hoshiyama, T., Ito, M., Kaneko, S., Kiyama, T., Kawahara, Y., Sumi, H., Tsuruta, Y., Kuyama, N., Hirakawa, K., Ishii, M., Tabata, N., Yamanaga, K., Fujisue, K., Hanatani, S., Sueta, D., Arima, Y., Araki, S., …, & Tsujita, K. (2024). Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia. Europace, 26(6). https://doi.org/10.1093/europace/euae155

Vancouver

Kanazawa H, Takashio S, Hoshiyama T, Ito M, Kaneko S, Kiyama T, et al. Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia. Europace. 2024;26(6). doi:10.1093/europace/euae155

BibTeX
@article{Kanazawa2024,
  author = {Kanazawa, Hisanori and Takashio, Seiji and Hoshiyama, Tadashi and Ito, Miwa and Kaneko, Shozo and Kiyama, Takuya and Kawahara, Yusei and Sumi, Hitoshi and Tsuruta, Yuichiro and Kuyama, Naoto and Hirakawa, Kyoko and Ishii, Masanobu and Tabata, Noriaki and Yamanaga, Kenshi and Fujisue, Koichiro and Hanatani, Shinsuke and Sueta, Daisuke and Arima, Yuichiro and Araki, Satoshi and Matsuzawa, Yasushi and Usuku, Hiroki and Nakamura, Taishi and Yamamoto, Eiichiro and Soejima, Hirofumi and Matsushita, Kenichi and Tsujita, Kenichi},
  title = {Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia},
  journal = {Europace},
  year = {2024},
  volume = {26},
  number = {6},
  doi = {10.1093/europace/euae155}
}
Kostenlos starten →